{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:28:36Z","timestamp":1788571716364,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074226 82030120"],"award-info":[{"award-number":["82074226 82030120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Qili Qiangxin Capsule (QQC), a Chinese patent medicine, is clinically effective in treating dilated cardiomyopathy (DCM). However, the meta-analysis of QCC combined with conventional western medicine (CWM) on DCM remains unexplored. This study aimed to systematically evaluate the efficacy and safety of QCC in the treatment of DCM.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Searched the studies of the combination of QQC and CWM in the treatment of DCM, from databases like PubMed, Cochrane Library, Web of Science, Wan Fang Databases, Chinese Biomedical Literature Database, China Science and Technology Journal Database, China National Knowledge Infrastructure, prior to 15 January 2022. Two reviewers respectively regulated research selection, data extraction, and risk of bias assessment. Review Manager Software 5.4 was used for meta-analysis. Furthermore, GRADE pro3.6.1 software was selected to grade the current evidence in our findings. This meta-analysis has been registered in PROSPERO (CRD42022297906).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> There were 35 studies pertaining to 3,334 patients included. The meta-analysis showed compared with CWM alone, the combination therapy had significant advantages in improving the clinical efficiency rate (RR = 1.24, 95% CI: 1.19 to 1.29, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), 6\u00a0min walking distance (6MWD) (MD = 41.93, 95%CI: 39.82 to 44.04, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), superior in ameliorating the left ventricular ejection fraction (LVEF) (MD = 5.73, 95%CI: 4.70 to 6.77, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), left ventricular end-diastolic dimension (LVEDD) (MD = \u22124.09, 95%CI: \u22124.91 to \u22123.27), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), left ventricular end-systolic diameter (LVESD) (MD = \u22124.73, 95%CI: \u22125.63 to \u22123.84), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001) and BNP (MD = \u2212101.09, 95%CI: -132.99 to \u221269.18), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), and also superior in reducing hypersensitive-C-Reactive Protein (hs-CRP) (MD = \u22123.78, 95%CI: \u22124.35 to \u22123.21), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), Interleukin- 6 (IL-6) (MD = \u221225.92, 95%CI: \u221231.35 to -20.50), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), tumor necrosis factor-\u03b1 (TNF-\u03b1) (MD = -5.04, 95%CI: \u22126.13 to \u22123.95), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), high mobility group protein B1 (HMGB1) (MD = \u22124.34, 95%CI: \u22125.22 to \u22123.46), <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), and adverse reactions (ARs) (RR = 0.70, 95%CI: 0.51\u20130.97), <jats:italic>p<\/jats:italic> = 0.03). The GRADE evidence quality rating presented with moderate or low quality of evidence for the available data.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Compared with the control group, QQC combined with CWM may be effective in treating DCM. However, the conclusion of this study must be interpreted carefully due to the inferior quality and ambiguity of bias in the included trials.<\/jats:p><jats:p><jats:bold>Systematic Review Registration<\/jats:bold>: <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero<\/jats:ext-link>, identifier [CRD42022297906].<\/jats:p>","DOI":"10.3389\/fphar.2022.893602","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T04:55:31Z","timestamp":1651121731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Jingjing","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1253\/circj.CJ-18-0063","article-title":"Inflammatory Mechanisms of Cardiovascular Remodeling","volume":"82","author":"Anzai","year":"2018","journal-title":"Circ. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE Guidelines: 3. Rating the Quality of Evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1756-5391.2010.01055.x","article-title":"Improving Reporting of Adverse Events and Adverse Drug Reactions Following Injections of Chinese Materia Medica","volume":"3","author":"Bian","year":"2010","journal-title":"J. Evid. Based Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"282114604","DOI":"10.1016\/j.jep.2021.114604","article-title":"Comparative Efficacy of Five Chinese Medicine Injections for Treating Dilated Cardiomyopathy with Heart Failure: A Bayesian Network Meta-Analysis","volume":"282","author":"Cao","year":"2022","journal-title":"J. Ethnopharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"W7","DOI":"10.7326\/M16-297710.7326\/IsTranslatedFrom_M17-2977_1","article-title":"CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration (Traditional Chinese Version)","volume":"167","author":"Cheng","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.13201\/j.issn.1001-1439.2018.05.001","article-title":"Chinese Guidelines for the Diagnosis and Treatment of Dilated Cardiomyopathy","volume":"34","year":"2018","journal-title":"J. Clin. Cardiol. (China)"},{"key":"B7","first-page":"242244","article-title":"Clinical Observation of Qili Qiangxin Capsule in the Treatment of Dilated Cardiomyopathy and Heart Failure","volume":"29","author":"Dai","year":"2019","journal-title":"China Heal Care Nutr."},{"key":"B8","first-page":"109","article-title":"Analysis on the Therapeutic Effect of Qili Qiangxin Capsule Combined with Recombinant Human Brain Natriuretic Peptide in the Treatment of Dilated Cardiomyopathy Complicated with Heart Failure","volume":"57","author":"Dong","year":"2019","journal-title":"China Mod. Dr"},{"key":"B9","first-page":"28","article-title":"Efficacy and Safety of Qili Qiangxin Capsule Combined with Valsartan in the Treatment of Dilated Cardiomyopathy Heart Failure","volume":"2021","author":"Fan","year":"2021","journal-title":"Health Manage."},{"key":"B10","first-page":"27","article-title":"Effect of Qiliqiangxin Capsule Combined with Digoxin on Cardiac Function of Patients with Dilated Cardiomyopathy with Mild and Moderate Heart Failure","volume":"15","author":"Fang","year":"2018","journal-title":"Drug Eval."},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of Pharmacological Treatment for Heart Failure in Patients with Recovered Dilated Cardiomyopathy (TRED-HF): an Open-Label, Pilot, Randomised Trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"B12","first-page":"205","article-title":"Clinical Observation of Qili Qiangxin Capsule in the Treatment of 30 Cases of Dilated Cardiomyopathy and Heart Failure","volume":"16","author":"Han","year":"2016","journal-title":"World Latest Med. Infor"},{"key":"B13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.16281\/j.cnki.jocml.2018.73.116","article-title":"Analysis of the Effect of Qili Qiangxin Capsule in the Treatment of Dilated Cardiomyopathy Heart Failure","volume":"5","author":"Hang","year":"2018","journal-title":"J. Clin. Med. Lit. Electron."},{"key":"B14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","article-title":"The Diagnosis and Evaluation of Dilated Cardiomyopathy","volume":"67","author":"Japp","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B16","first-page":"1840","article-title":"Clinical Study on Qili Qiangxin Capsules Combined with Recombinant Human Brain Natriuretic Peptide in Treatment of Dilated Cardiomyopathy with Heart Failure","volume":"32","author":"Jing","year":"2017","journal-title":"Drugs Clin."},{"key":"B17","first-page":"103","article-title":"Effect of Qili Qiangxin Capsule Combined with Anti-heart Failure in the Treatment of Dilated Cardiomyopathy Heart Failure on Plasma Brain Natriuretic Peptide Level and Cardiac Function","volume":"36","author":"Leng","year":"2016","journal-title":"J. Hunan Univ. Tradit Chin. Med."},{"key":"B18","first-page":"87","article-title":"Effects of Qili Qiangxin Capsule on NT-proBNP Level and Cardiac Function in Patients with Dilated Cardiomyopathy","volume":"2020","author":"Li","year":"2020","journal-title":"Home Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"10651065","DOI":"10.1016\/j.jacc.2013.05.035","article-title":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effects of Qili Qiangxin Capsules in Patients with Chronic Heart Failure","volume":"6262","author":"Li","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B20","first-page":"159","article-title":"Observation on the Curative Effect of Qili Qiangxin Capsule in Adjuvant Treatment of Dilated Cardiomyopathy with Cardiac Insufficiency","volume":"8","author":"Liu","year":"2009","journal-title":"Chin. J. Diffic Compl Cas"},{"key":"B21","first-page":"158","article-title":"Clinical Study of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Dilated Cardiomyopathy-Induced Heart Failure","volume":"25","author":"Liu","year":"2019","journal-title":"Contemp. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.hlc.2014.02.022","article-title":"Clinical Characteristics and Long-Term Prognosis in Patients with Chronic Heart Failure and Reduced Ejection Fraction in China","volume":"23","author":"Liu","year":"2014","journal-title":"Heart Lung Circ."},{"key":"B23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3969\/j.issn.1001-1978.2016.04.026","article-title":"Effects of Qili Qiangxin Capsule on the RAS System and Sympathetic Nervous System of the Hypothalamic Paraventricular Nucleus in Rats with Chronic Heart Failure","volume":"32","author":"Ma","year":"2016","journal-title":"Chin. Pharmacol. Bull."},{"key":"B24","first-page":"41","article-title":"Observation on the Effect of Qili Qiangxin Capsule in Adjuvant Treatment of Dilated Cardiomyopathy","volume":"2016","author":"Ma","year":"2016","journal-title":"Women\u2019s Heal Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","article-title":"Contemporary Definitions and Classification of the Cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention","volume":"113","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"B26","first-page":"118","article-title":"Effects of Qili Qiangxin Capsule Combined with Recombinant Human Brain Natriuretic Peptide on Cardiac Function and Daily Living Ability in Patients with Dilated Cardiomyopathy and Heart Failure","volume":"116","author":"Meng","year":"2020","journal-title":"Chang Shou"},{"key":"B27","first-page":"53","article-title":"Analysis of the Effect of Qili Qiangxin Capsule Combined with Telmisartan in the Treatment of Dilated Cardiomyopathy","volume":"2021","author":"Niu","year":"2021","journal-title":"Health Horizon"},{"key":"B28","first-page":"2879","article-title":"Efficacy Analysis of Qili Qiangxin Capsule Combined with Metoprolol in the Treatment of Patients with Dilated Cardiomyopathy","volume":"31","author":"Niu","year":"2020","journal-title":"Mod. Diagn. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jcmg.2021.03.015","article-title":"Myocardial Fibrosis in Dilated Cardiomyopathy: Moving from Stratifying Risk to Improving Outcomes","volume":"14","author":"Prasad","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/joim.12944","article-title":"Dilated Cardiomyopathy: from Epidemiologic to Genetic Phenotypes: A Translational Review of Current Literature","volume":"286","author":"Reichart","year":"2019","journal-title":"J. Intern. Med."},{"key":"B31","first-page":"102103","article-title":"Effects of Qili Qiangxin Capsule on Cardiac Function and Expression of High Mobility Group Box Protein B1 in Patients with Dilated Cardiomyopathy","volume":"2015","author":"Ren","year":"2015","journal-title":"Med. Heal Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3969\/j.issn.1671-5217.2020.02.124","article-title":"Analysis of the Effect of Qili Qiangxin Capsule Combined with Immunoglobulin in the Treatment of Elderly Patients with Dilated Cardiomyopathy","volume":"2020","author":"Shi","year":"2020","journal-title":"Health Lit."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12350-020-02202-4","article-title":"Parameters of Left Ventricular Systolic and Diastolic Dyssynchrony on Radionuclide Imaging to Improve Cardiac Resynchronization Therapy in Heart Failure Patients with Dilated Cardiomyopathy","volume":"28","author":"Sreenivasan","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"B34","first-page":"831","article-title":"Clinical Observation of Qili Qiangxin Capsule in Treating Dilated Cardiomyopathy Heart Failure","volume":"21","author":"Sun","year":"2012","journal-title":"J. Emerg. Tradit Chin. Med."},{"key":"B35","first-page":"2238","article-title":"Clinical Study on Qili Qiangxin Capsules Combined with Levosimendan in Treatment of Dilated Cardiomyopathy Complicated with Heart Failure","volume":"35","author":"Wang","year":"2020","journal-title":"Drugs Clin."},{"key":"B36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3969\/j.issn.9128-6509.2018.11.198","article-title":"Clinical Observation of Qili Qiangxin Capsule in the Treatment of Dilated Cardiomyopathy","volume":"27","author":"Wang","year":"2018","journal-title":"Health Forefront"},{"key":"B37","first-page":"3620","article-title":"Clinical Study of Sacubitril-Valsartan Combined with Qiliqiangxin Capsule in the Treatment of Dilated Cardiomyopathy Heart Failure","volume":"18","author":"Wang","year":"2020","journal-title":"Chin. J. Integr. Med. Cardio-\/Cerebrovascuiar Dis."},{"key":"B38","first-page":"1568","article-title":"Efficacy Observation of Qili Qiangxin Capsule Combined with Immunoglobulin in the Treatment of Senile Dilated Cardiomyopathy","volume":"28","author":"Wang","year":"2019","journal-title":"Mod. J. Integrat Trad Chin. West. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(16)31713-5","article-title":"Dilated Cardiomyopathy","volume":"390","author":"Weintraub","year":"2017","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.13201\/j.issn.1001-1439.2013.02.004","article-title":"Expression of High Mobility Group Box 1 Protein, Interleukin-6 and Tumor Necrosis Factor-\u03b1 in Serum of Patients with Dilated Cardiomyopathy","volume":"29","author":"Wu","year":"2013","journal-title":"J. Clin. Cardiol. (China)"},{"key":"B41","first-page":"271","article-title":"Influences of Qili Qiangxin Capsules on Heart Function and Expression of High Mobility Group Box 1 Protein (HMGB1) in Patients with Dilated Cardiomyopathy","volume":"6","author":"Wu","year":"2014","journal-title":"Chin. J. Evid-based Cardiovasc. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"698056","DOI":"10.3389\/fcvm.2021.698056","article-title":"Traditional Chinese Medication Qiliqiangxin Attenuates Diabetic Cardiomyopathy via Activating PPAR\u03b3","volume":"8","author":"Wu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B43","first-page":"329","article-title":"The Clinical Study of the Influence of Qiliqiangxin Capsule to the Heart Function and Vascular Endothelial Function of the Patients with Dilated Cardiomyopathy","volume":"17","author":"Wu","year":"2018","journal-title":"Chin. J. Diffic Compl Cas"},{"key":"B44","first-page":"273","article-title":"Effect of Qiliqiangxin Capsule on Cardiac Function and \u03b21, M2 Receptor Autoantibodies in Patients with Dilated Cardiomyopathy","volume":"12","author":"Yang","year":"2013","journal-title":"Chin. J. Diffic Compl Cas"},{"key":"B45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.13422\/j.cnki.syfjx.20191332","article-title":"Effect Research Antiventricular Remodeling of Qili Qiangxin Capsules in Treating Dilated Cardiomyopathy","volume":"25","author":"Yang","year":"2019","journal-title":"Chin. J. Exp. Tradit Med. Formulae"},{"key":"B46","first-page":"1059","article-title":"Observation on the Effect of Qili Qiangxin Capsule on Chronic Heart Failure Caused by Dilated Cardiomyopathy","volume":"27","author":"Yao","year":"2018","journal-title":"Henan Med. Res."},{"key":"B47","first-page":"1363","article-title":"Influences of QiliQiangxin Capsule Combined with Telmisartanon Cardiac Function of Patients with Dilated Cardiomyopathy","volume":"18","author":"Yao","year":"2020","journal-title":"Chin. J. Integr. Med. Cardio-\/Cerebrovascuiar Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"254","DOI":"10.15912\/j.cnki.gocm.2014.35.200","article-title":"Effects of Qili Qiangxin Capsule on Cardiac Function and Plasma Brain Natriuretic Peptide Level in Patients with Dilated Cardiomyopathy","volume":"12","author":"Yi","year":"2014","journal-title":"Chin. Med. Guide"},{"key":"B49","first-page":"40","article-title":"Effects of Qiliqiangxin Capsule on Cardiac Function and Levels of Serum Brain Natriuretic Peptide in Dilated Cardiomyopathy Patients with Heart Failure","volume":"14","author":"Yuan","year":"2012","journal-title":"J. Chin. Mod. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3389\/fphar.2019.01046","article-title":"Integrating Pharmacokinetics Study, Network Analysis, and Experimental Validation to Uncover the Mechanism of Qiliqiangxin Capsule against Chronic Heart Failure","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B51","first-page":"221","article-title":"Clinical Observation of Qili Qiangxin Capsule in the Treatment of Dilated Cardiomyopathy Heart Failure","volume":"21","author":"Zhang","year":"2013","journal-title":"Chin. J. Trauma Disabil. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.16050\/j.cnki.issn1674-6309.2018.10.026","article-title":"Application of Qili Qiangxin Capsule in the Treatment of Patients with Dilated Cardiomyopathy and Heart Failure","volume":"40","author":"Zhao","year":"2018","journal-title":"Ningxia Med. J."},{"key":"B53","first-page":"112","article-title":"Effects of Qili Qiangxin Capsule Combined with Recombinant Human Brain Natriuretic Peptide on Cardiac Function and Daily Living Ability in Patients with Dilated Cardiomyopathy and Heart Failure","volume":"48","author":"Zheng","year":"2019","journal-title":"Heilongjiang J. Tradit Chin. Med."},{"key":"B54","first-page":"837","article-title":"Effects of Qili Qiangxin Capsule on Cardiac Function and Cold-Induced RNA-Binding Protein Expression in Patients with Dilated Cardiomyopathy","volume":"25","author":"Zhou","year":"2015","journal-title":"Zhejiang J. Integr. Tradit Chin. West. Med."},{"key":"B55","first-page":"549","article-title":"40 Cases of Dilated Cardiomyopathy Treated by Qili Qiangxin Capsule","volume":"31","author":"Zhu","year":"2010","journal-title":"Shanxi Trad Chin. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1819794","DOI":"10.1155\/2016\/1819794","article-title":"Oral Chinese Herbal Medicine for Treatment of Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis","volume":"2016","author":"Zhu","year":"2016","journal-title":"Evid. Based Complement. Alternat Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.893602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T04:56:18Z","timestamp":1651121778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.893602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":56,"alternative-id":["10.3389\/fphar.2022.893602"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.893602","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"893602"}}